News Center | 2021-04-15 18:37:00
Ennovation Ventures Portfolio丨Clinical CRO service provider "Bestida" plans to be listed on A-shares

Baishida (Shanghai) Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Baishida") recently signed a listing counseling agreement with Orient Securities, which officially launched the A-share listing counseling. On March 30 this year, Baishida completed the shareholding reform, and changed from Shanghai Baishida Pharmaceutical Technology Co., Ltd. to Baishida (Shanghai) Pharmaceutical Technology Co., Ltd.
      Founded in 2010, Bestra is a clinical CRO (Contract Research Organization) company whose main business is to provide professional R&D outsourcing services in the clinical trial stage to pharmaceutical companies and medical device companies. At present, Baixida is a leading domestic innovative drug clinical development institution that provides high-quality clinical research services for domestic and foreign pharmaceutical and medical device companies. Mainly to provide clinical trial design, organization, operation and management services, including I-IV drug clinical trial and medical device clinical trial project registration application, protocol writing, base screening, clinical monitoring services, drug management, data management and Biostatistics, research report writing, etc. It has a senior professional research team, and the main researchers have work experience in the drug research and development department and clinical research department of foreign pharmaceutical companies.

      Besttech has an international and standardized business operation process and a scientific and rigorous quality assurance system, and is familiar with the operation and management of international multi-center clinical trials and various types of domestic clinical trial projects. He has close cooperation with domestic experts in various therapeutic fields, especially cardiovascular and cerebrovascular, respiratory, nephrology, metabolism, autoimmune, and oncology experts. Headquartered in Shanghai, the company has established branches in Beijing, Guangzhou, Chengdu, and Wuhan. Since its establishment 9 years ago, it has carried out projects with more than 300 domestic hospitals (more than 30 provinces and more than 60 cities), and is familiar with the domestic clinical research process. Passed the audit of 30+ internationally renowned pharmaceutical companies, participated in the registration application, clinical design and project management of 80+ new drugs, and undertaken 200+ Phase I-III registered clinical research projects.
      So far,Baixida has carried out projects in more than 300 hospitals in China (more than 30 provinces and 60 cities), passed the audit of 30+ internationally renowned pharmaceutical companies, and participated in the registration application, clinical design and project management of 80+ new drugs. Undertook 200+ Phase I-III registration clinical research projects.
       In September 2020, Baishida announced the completion of the B round of financing of over 100 million yuan.
In 2018, Baishida also received Series A investment from institutions such as CCB Capital and Wygar Capital.

       According to the official disclosure at that time, after the completion of the B round of financing, Bestard will further expand the scale of its staff and regional coverage, strengthen the construction of clinical service teams, and increase investment in information systems related to clinical trials, in order to stabilize the business of large multinational pharmaceutical companies. At the same time, it has rapidly improved its ability to serve domestic leading innovative pharmaceutical companies. In addition, Bestard will also speed up the pace of developing the international market, accelerate the business development of the US branch and the Australian subsidiary, and focus on improving the service capabilities of innovative medicine and medical design, data statistics, tumor medical imaging and other aspects.Build it into a one-stop platform for clinical development that provides high-quality clinical research services at home and abroad.